Development-stage pain products

Innovatve topical for Psoriasis

We are interested in Co- development of an innovative topical formulation presented in a delivery system particularly targeted for treatment of Psoriasis and other dermatoses of hyperkeratotic nature. The formulation comprises of ingredients having anti inflammatory and a keratosolvent properties. The innovative formulation presented in a specially designed delivery system is patent potential and has superior clinical efficacy as compared to topical keratolytics such as Salicylic Acid, coal tar and synthetic retinoids.

Variant of Tumor Necrosis Factor

TNF-α has been clinically proven as a tumor killing agent. M3S is a TNF-α Mutein (a variant of TNF-α) proven to have superior anti-tumor activity and safety compared to natural form. 

There is on-going development of generic EU CTD Dossier of Levetiracetam, tablets, 250/500/750/1000 mg.

DCP slot confirmed.

Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.